LGR5 was demonstrated as an important downstream target of β-catenin signaling (21, 22), and aberrant LGR5 expression reduced apoptosis in gastric cancer cells treated with 5-FU and oxaliplatin by suppressing caspase 3 cleavage. The gene discussed is LGR5; the disease is gastric cancer.